Establishment of a Novel Triage System for SARS-CoV-2 Among Trauma Victims in Trauma Centers with Limited Facilities
Overview
Authors
Affiliations
Objectives: The triage of trauma patients with potential COVID-19 remains a major challenge given that a significant number of patients may be asymptomatic or pre-symptomatic. This study aimed to compare the specificity and sensitivity of available triage systems for COVID-19 among trauma patients. Furthermore, it aimed to develop a novel triage system for SARS-CoV-2 detection among trauma patients in centers with limited resources.
Methods: All patients referred to our center from February to May 2020 were enrolled in this prospective study. We evaluated the SARS-CoV-2 triage protocols from the WHO, the Iranian Ministry of Health and Medical Education (MOHME), and the European Centre for Disease Control and Prevention (ECDC) for their effectiveness in finding COVID-19 infected individuals among trauma patients. We then used these data to design a stepwise triage protocol to detect COVID-19 positive patients among trauma patients.
Results: According to our findings, the WHO protocol showed 100% specificity and 13.3% sensitivity. The MOHME protocol had 99% specificity and 23.3% sensitivity. While the ECDC protocol showed 93.3% sensitivity and 89.5% specificity, it did not prioritize patients based on traumatic injuries and unstable conditions. Our stepwise triage protocol, which prioritizes traumatic injuries, had 93.3% sensitivity and 90.3% specificity.
Conclusion: Our study shows that the triage protocols from the WHO, MOHME and ECDC are not best equipped to diagnose SARS-CoV-2 infected individuals among trauma patients. In our proposed stepwise triage system, patients are triaged according to their hemodynamic conditions, COVID-19 related clinical states, and COVID-19 related laboratory findings. Our triage model can lead to more accurate and resource-effective management of trauma patients with potential COVID-19 infection.
Level Of Evidence: Level Ⅲ.
Clancy J, Hoffmann C, Pickett B Comput Struct Biotechnol J. 2023; 21:1403-1413.
PMID: 36785619 PMC: 9908618. DOI: 10.1016/j.csbj.2023.02.003.
Sabetian G, Abdolrahimzadeh Fard H, Ostovan M, Azadikhah S, Zand F, Masjedi M Bull Emerg Trauma. 2022; 10(4):172-180.
PMID: 36568719 PMC: 9758711. DOI: 10.30476/BEAT.2022.96357.1387.
Mirghaderi S, Salimi M, Moharrami A, Hosseini-Dolama R, Mirghaderi S, Ghaderi M Arthroplast Today. 2022; 18:76-83.
PMID: 36185411 PMC: 9513341. DOI: 10.1016/j.artd.2022.09.005.
Abdolrahimzadeh Fard H, Borazjani R, Shams A, Rezaee V, Aminnia S, Salimi M Bull Emerg Trauma. 2022; 10(3):128-134.
PMID: 35991375 PMC: 9373054. DOI: 10.30476/BEAT.2022.94720.1344.
Mirghaderi S, Sheikhbahaei E, Salimi M, Mirghaderi S, Ahmadi N, Moharrami A Ann Med Surg (Lond). 2022; 80:104307.
PMID: 35936568 PMC: 9343069. DOI: 10.1016/j.amsu.2022.104307.